GlassScriptPhysician profile
Javier E Aisenberg
NPI 1053364000
$9,667.79
in general payments reported to CMS, 2019-2025
11 companies · $2,345 in 2025
The $2,345 reported for 2025 was more than what 78% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,383 · 2021: $450 · 2022: $19.26 · 2023: $1,174 · 2024: $296 · 2025: $2,345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,125 · Honoraria: $950 · Food and Beverage: $740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,125.00 |
| Honoraria | $950.00 |
| Food and Beverage | $740.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $3,273.28 | 2019 | |
| Mannkind Corporation | $2,209.99 | 2025 | |
| Medtronic Minimed, INC. | $1,322.61 | 2019 | |
| Tolmar, INC. | $967.27 | 2023-2025 | Fensolvi |
| Tandem Diabetes Care, INC. | $787.52 | 2019 | |
| Abbvie INC. | $450.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $239.23 | 2024-2025 | |
| Biomarin Pharmaceutical INC. | $118.42 | 2024 | Voxzogo 1.2mg |
| Medtronic, INC. | $103.73 | 2022-2024 | Minimed 780g |
| Rhythm Pharmaceuticals, INC. | $101.30 | 2023 | Imcivree |
| Glaxosmithkline, LLC. | $94.44 | 2023-2024 | Nucala |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Aisenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.